EA201101663A1 - COVALENT CONJUGATE OF POLYETHYLENE GLYCOL WITH GRANULOCITARIAN COLONIUS STIMULATING FACTOR OF THE PERSON - Google Patents
COVALENT CONJUGATE OF POLYETHYLENE GLYCOL WITH GRANULOCITARIAN COLONIUS STIMULATING FACTOR OF THE PERSONInfo
- Publication number
- EA201101663A1 EA201101663A1 EA201101663A EA201101663A EA201101663A1 EA 201101663 A1 EA201101663 A1 EA 201101663A1 EA 201101663 A EA201101663 A EA 201101663A EA 201101663 A EA201101663 A EA 201101663A EA 201101663 A1 EA201101663 A1 EA 201101663A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- stimulating factor
- person
- polyethylene glycol
- granulocitarian
- colonius
- Prior art date
Links
Abstract
Изобретение относится к медицине и биотехнологии и касается ковалентного конъюгата полиэтиленгликоля с гранулоцитарным колониестимулирующим фактором человека, в котором ПЕГ присоединен к тирозиновым или гистидиновым фрагментам полипепетида посредством азогруппы общей структуры (I)где n - целое число в интервале от 100 до 1200; А - аминокислотный фрагмент тирозина или гистидина; Г-КСФ - гранулоцитарный колониестимулирующий фактор. Конъюгат Г-КСФ обладает большим временем циркуляции в кровотоке по сравнению с немодифицированным полипепетидом при сохранении существенной доли его активности.The invention relates to medicine and biotechnology and relates to a covalent conjugate of polyethylene glycol with a granulocyte colony-stimulating factor of a person, in which PEG is attached to the tyrosine or histidine fragments of polypeptide by the azo group of general structure (I) where n is an integer in the range from 100 to 1200; A - amino acid fragment of tyrosine or histidine; G-CSF - granulocyte colony-stimulating factor. The G-CSF conjugate has a longer circulation time in the bloodstream compared with the unmodified polypeptide, while maintaining a significant proportion of its activity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201101663A EA020425B1 (en) | 2011-12-21 | 2011-12-21 | Polyethyleneglycol covalent conjugate with granulocytic colony-stimulating human factor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201101663A EA020425B1 (en) | 2011-12-21 | 2011-12-21 | Polyethyleneglycol covalent conjugate with granulocytic colony-stimulating human factor |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201101663A1 true EA201101663A1 (en) | 2013-06-28 |
EA020425B1 EA020425B1 (en) | 2014-11-28 |
Family
ID=48699367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201101663A EA020425B1 (en) | 2011-12-21 | 2011-12-21 | Polyethyleneglycol covalent conjugate with granulocytic colony-stimulating human factor |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA020425B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA029942B1 (en) * | 2014-06-16 | 2018-06-29 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Stable pharmaceutical composition based on conjugates of biologically active proteins with polyethylene glycol containing an azo group |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2749509C1 (en) * | 2020-07-28 | 2021-06-11 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Targeted colony-stimulating agent |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0816381B1 (en) * | 1995-03-10 | 2004-01-14 | NAKAMURA, Toshikazu | Polyethylene glycol modified hepatocyte growth factor (hgf) |
RU2400490C2 (en) * | 2003-12-03 | 2010-09-27 | Биодженерикс Аг | Glyco-peg granulocyte colony-stimulating factor |
-
2011
- 2011-12-21 EA EA201101663A patent/EA020425B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA029942B1 (en) * | 2014-06-16 | 2018-06-29 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Stable pharmaceutical composition based on conjugates of biologically active proteins with polyethylene glycol containing an azo group |
Also Published As
Publication number | Publication date |
---|---|
EA020425B1 (en) | 2014-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3211001A3 (en) | Superagonists and antagonists of interleukin-2 | |
EA201200515A1 (en) | POLYPEPTIDES AND THEIR APPLICATION | |
CY1116728T1 (en) | FACTORS AFFECTING CANCER AND IMMUNE AND AUTOMATIC DISEASES TREATMENT | |
EA201190080A1 (en) | STABLE FORMS OF GRANULOCITARIAN COLONIES OF RECOMBINANT HUMAN ALBUMIN, STIMULATING FACTOR OF A HYBRID PROTEIN | |
EP3456339A3 (en) | Novel immunotherapy against several tumors, such as lung cancer including nsclc | |
MX2020011674A (en) | Diagnosis and treatment of cancer based on avl9. | |
PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
EA201290395A1 (en) | IMMUNOMODULATING POLYPEPTIDES OBTAINED FROM IL-2 AND THEIR USE FOR THE TREATMENT OF CANCER AND CHRONIC INFECTIONS | |
EA201201661A1 (en) | NEW AMINOPYRAZOLOHINAZOLINES | |
BR112013031262A2 (en) | "exotoxins a from pseudomonas with less immunogenic bet cell epitopes, and their use in cancer treatment and prevention, as well as chimeric molecule, nucleic acid, expression vector, cells, pharmaceutical composition and methods to inhibit target cell growth and endotoxin production and pseudomonas and chimeric molecule ". | |
MX2015006374A (en) | Anti-ceacam5 antibodies and uses thereof. | |
EA201201305A1 (en) | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCER TYPES | |
CO7010783A2 (en) | Recombinant human naglu protein and uses thereof | |
EA201492053A1 (en) | PROTEINS OF FIBROBLAST GROWTH FACTOR 21 | |
WO2012069568A3 (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
EA201001691A1 (en) | ANTIBODIES TO GRANULOCYTER-MACROPHAGAL COLONIUS STIMULATING FACTOR | |
EA201270419A1 (en) | GUANGZHETINE DREAMS | |
EA201490378A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β | |
EA201500261A1 (en) | ANTIBODY AND MEDICINE CONJUGATES (ADC) THAT ARE ASSOCIATED WITH PROTEINS 158P1D7 | |
EA201991704A3 (en) | MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR WAY INHIBITOR (TFPI) | |
MX2014004953A (en) | Tyrosine based linkers for the releasable connection of peptides. | |
EA201491369A1 (en) | METHOD OF TREATING DIABETES MELLITUS WITH NON-GLYCOLYNED APOLYPOPROTEIN A-IV | |
EA201490032A1 (en) | LYOPHYLIZED PREPARATIONS FGF-18 | |
EA201590601A1 (en) | APPLICATION OF PEDF-DERIVED POLYPEPTIDES FOR THE TREATMENT OF OSTEOARTHRITIS | |
CY1118967T1 (en) | HIGH-DOSE BIOTINE PHARMACEUTICAL COMPOSITIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |